GSK plc GSK
50.60 USD -0.63 (-1.23%)
At closeNov 11, 2026, 4:02 PM EST
50.60 0.00 0.00%
After hours · Nov 11, 4:02 PM ET
49.79 Day range 50.64
45.81 52-week range 61.70
- YTD
- +3.18%
- 1 year
- +4.52%
News
marketbeat.com GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease,…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Healthcare dividend stocks PRGO (7.32%), BMY (4.06%) and GSK (3.65%) feature analyst ratings and recent company news.
reuters.com GSK, Moderna settle patent dispute over Moderna COVID, RSV shots GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
benzinga.com ViiV Healthcare Commits $100M Over Three Years Under Its U.S. Positive Action Program To Support Local HIV Organizations ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced a $100 million, three-year commitment through its U.S. Positive Action…
benzinga.com From Pharmaceuticals to PCs: HP Bets on Emma Walmsley to Navigate Chip Crisis HP stock rises as former GSK CEO Emma Walmsley is named chief amid soaring memory costs, declining PC shipments and growing AI opportunities.
nypost.com HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEO HP, like peers Dell Technologies, Apple and Lenovo, is caught in a global memory chip squeeze.
benzinga.com Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc…
benzinga.com Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9 Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
benzinga.com GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat GSK beat Q3 analyst consensus with $1.47 adjusted EPS and $11.95 billion revenue, as specialty drugs offset vaccine drops. 2026 outlook reaffirmed.
benzinga.com UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
benzinga.com GSK Q3 2026 Earnings Call Transcript GSK (NYSE:GSK) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…- benzinga.com GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.78 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.150B Est GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.78 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.150 billion…
benzinga.com GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate GSK (NYSE:GSK) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.40 by 5 percent. This is a 0.68 percent decrease over earnings of $1.48 per share from…
benzinga.com Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco…- benzinga.com Wave Life Sciences Anticipates $12M Milestone Payment From GSK In Q4 Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results…
- benzinga.com GSK’s Ris-Rez Meets Primary Endpoint In Phase III ARTEMIS-011 Trial, Reducing Risk Of Progression Or Death By 67%, Improving Median Progression-Free Survival To 5.5 Months Vs. 1.4 Months With Chemotherapy In Relapsed Or Refractory Osteosarcoma Patients receiving Ris-Rez remained progression-free for a median of 5.5 months versus 1.4 months with comparatorSecond positive phase III trial in China adds to growing body of late-stage evidence…
benzinga.com Reported Saturday, GSK’s Jemperli Monotherapy Shows Generally Consistent Safety, With Serious Adverse Reactions In 20% And Discontinuations In 3%, Alongside 76% Complete Response In Phase II AZUR-1 MSI-H/dMMR Rectal Cancer Trial Patients had no evidence of cancer following treatment with Jemperli alone, as confirmed by endoscopy, radiology and/or pathologyNo disease recurrences reported among responders after median…
benzinga.com GSK Wins FDA Approval For Chronic Hepatitis B Drug FDA clears GSK Hibsago for chronic hepatitis B in adults, delivering strong functional cure rates and suppressing viral replication targets.
benzinga.com FDA Clears GSK Drug That Could Change How Certain Rectal Cancers Are Treated FDA approves GSK's Jemperli as first immunotherapy for dMMR/MSI-H rectal cancer, offering a surgery-free alternative.
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Analysts review high-yield healthcare stocks CVS, Medtronic and GSK, offering dividend yields of 3.02%-3.86% and varied ratings.
benzinga.com Why Is GSK Stock Gaining Monday? GSK shares jump over 4% on strong survival data for SCLC drug Ris-Rez and a 94% response rate for Jideytro in NSCLC.- benzinga.com GSK's Jideytro Achieves 94% Objective Response Rate At 15.2 Months Follow-Up In TKI-Naïve ROS1-Positive NSCLC, ARROS-1 Trial Shows 94% objective response rate at 15.2 months follow-up90% of patients were progression free at 12 months, with median PFS rate still to be reached70% of patients with measurable brain metastases…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields Analyst ratings and news for high-yield healthcare stocks Medtronic (3.06%), Smith & Nephew (2.74%) and GSK (3.65%).
benzinga.com 8 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
benzinga.com Why Is HUTCHMED Stock Soaring Thursday? HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
benzinga.com GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors GSK moves its dual-target mRNA seasonal flu vaccine to Phase 3 trials following strong Phase 2 data and FDA Fast Track status.
benzinga.com Measles Kills 2 in Pennsylvania: What Do Prediction Markets Say About the Disease? Two unvaccinated Pennsylvania residents died of measles, the state’s first deaths in 35 years, as traders see 89% odds of 4,000 U.S. cases.
benzinga.com Dr. Oz Says The MMR Vaccine Is Not 'Lethal' as Trump Administration Faces Questions Over Vaccine Policy Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst ratings for high-yield stocks in health care.
benzinga.com Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong' (UPDATED) President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.- benzinga.com Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children https://youtu.be/H_RititNE8U
benzinga.com Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions' The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.- benzinga.com GSK Announces Cabenuva Demonstrates Superiority To Daily Oral Therapy In Adolescents Living With HIV, As Viiv Healthcare Highlights New Long-Acting Injectable Data At AIDS 2026 https://www.gsk.com/en-gb/media/press-releases/cabenuva-demonstrates-superiority-to-daily-oral-therapy-in-adolescents-living-with-hiv-as-viiv-healthcare-highlights-new-long-acting-injectable-data-at-a…
benzinga.com GSK Races To Protect Profits Before Its HIV Blockbuster Faces Generic Rivals GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its 2026 guidance.
benzinga.com Sherwin-Williams Posts Upbeat Q2 Earnings, Joins Itron, Armstrong World And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting better-than-expected earnings and raising FY26 guidance.
benzinga.com Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields In times of market turbulence, dividend-yielding stocks are popular for investors. Check out analyst ratings for high-yielding stocks and recent news on Bristol-Myers Squibb, GSK, and Medtronic PLC…
benzinga.com GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion…- benzinga.com GSK Q2 Adj. EPS $1.35 Beats $1.27 Estimate, Sales $11.280B Beat $10.790B Estimate GSK (NYSE:GSK) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.27 by 6.3 percent. This is a 8.87 percent increase over earnings of $1.24 per share from…
- benzinga.com GSK Licensor Hansoh Pharma Announces Results From Second Phase III Trial For Ris-Rez In China; Study Met Its Primary Endpoint Of Progression-Free Survival In Relapsed Osteosarcoma Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal data in advanced or relapsed small-cell lung cancerGSK is advancing development of Ris-Rez outside…
- benzinga.com GSK Canada Receives Approval For Shingrix Zoster Vaccine In Prefilled Syringe GSK Canada today announced the approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in a prefilled syringe. This new presentation removes the need to reconstitute separate vials prior to…
benzinga.com FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
benzinga.com GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally…
benzinga.com Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.
benzinga.com Disappointing Data Prompts GSK to Drop Cough Drug Development GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testing it for irritable bowel disease.
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three…
benzinga.com GSK's Jemperli May Help Some Rectal Cancer Patients Avoid Surgery GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.
benzinga.com GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.